We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+15.34%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$338M
AUM Growth
+$65.4M
Cap. Flow
+$44.6M
Cap. Flow %
13.18%
Top 10 Hldgs %
27.92%
Holding
106
New
39
Increased
24
Reduced
12
Closed
28

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$8.7M
2
GSK icon
GSK
GSK
+$7.94M
3
CNC icon
Centene
CNC
+$7.26M
4
EXAS
Exact Sciences
EXAS
+$6.94M
5
SHPG
Shire pic
SHPG
+$6.83M

Top Sells

Rank Stock Value
1
ATHN
Athenahealth, Inc.
ATHN
+$9.99M
2
IEV icon
iShares Europe ETF
IEV
+$7.22M
3
NUVA
NuVasive, Inc.
NUVA
+$7.07M
4
HUM icon
Humana
HUM
+$6.83M
5
AET
Aetna Inc
AET
+$4.84M

Sector Composition

Rank Sector Weight
1 Healthcare 73.98%
2 Financials 0%
3 Industrials 0%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIOX
26
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.68M 1.68%
+47,500
New +$4.98M
AVXS
27
DELISTED
AveXis, Inc. Common Stock
AVXS
$5.52M 1.63%
72,625
+20,250
+39% +$1.25M
CELG
28
DELISTED
Celgene Corp
CELG
$5.47M 1.62%
+44,000
New +$5.27M
WAT icon
29
CALL
Waters Corp
WAT
$39.9B
$5.47M 1.62%
+35,000
New +$5.23M
WMGI
30
DELISTED
Wright Medical Group Inc
WMGI
$5.45M 1.61%
175,000
+35,000
+25% +$949K
LLY icon
31
Eli Lilly
LLY
$1.06T
$5.4M 1.6%
+64,250
New +$5.15M
SUPN icon
32
Supernus Pharmaceuticals
SUPN
$2.77B
$5.4M 1.6%
172,500
+117,500
+214% +$3.15M
ABBV icon
33
AbbVie
ABBV
$435B
$5.38M 1.59%
82,625
-67,750
-45% -$4.26M
PEN icon
34
Penumbra
PEN
$12.8B
$5.22M 1.54%
62,555
-32,445
-34% -$2.46M
IWM icon
35
PUT
iShares Russell 2000 ETF
IWM
$81.9B
$5.16M 1.52%
37,500
-22,500
-38% -$3.07M
QGENF
36
DELISTED
QIAGEN NV
QGENF
$4.42M 1.31%
+152,500
New +$4.42M
MEDP icon
37
Medpace
MEDP
$16.5B
$4.34M 1.28%
145,282
+42,775
+42% +$1.38M
ABMD
38
CALL
DELISTED
Abiomed Inc
ABMD
$4.26M 1.26%
+34,000
New +$3.94M
SIEN
39
DELISTED
Sientra, Inc.
SIEN
$4.25M 1.26%
50,480
+480
+1% +$42.3K
PODD icon
40
Insulet
PODD
$9.79B
$4.19M 1.24%
+97,256
New +$4.17M
KTWO
41
DELISTED
K2M Group Holdings, Inc
KTWO
$4.16M 1.23%
202,907
-39,293
-16% -$807K
ADMS
42
DELISTED
Adamas Pharmaceuticals
ADMS
$4.16M 1.23%
+237,500
New +$4.05M
TEVA icon
43
Teva Pharmaceuticals
TEVA
$41.2B
$4.01M 1.19%
+124,875
New +$4.26M
XLV icon
44
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.3B
$3.72M 1.1%
50,000
-122,500
-71% -$8.93M
IMMU
45
DELISTED
Immunomedics Inc
IMMU
$3.53M 1.04%
545,000
+208,500
+62% +$1.06M
SUPN icon
46
PUT
Supernus Pharmaceuticals
SUPN
$2.77B
$3.29M 0.97%
+105,000
New +$2.81M
ARAY icon
47
Accuray
ARAY
$34M
$3.25M 0.96%
685,100
+386,307
+129% +$2.01M
DXCM icon
48
DexCom
DXCM
$32B
$2.97M 0.88%
+140,000
New +$2.73M
NSTG
49
DELISTED
NanoString Technologies, Inc.
NSTG
$2.84M 0.84%
142,750
-18,561
-12% -$353K
NDRM
50
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.76M 0.82%
103,850
+23,667
+30% +$586K
1
2
3 4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
ONGA
O'Neil Global Advisors Los Angeles, California $14.4M AUM 220.73% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM

Pura Vida Investments's Q1 2017 Portfolio in Review

As of Q1 2017, Pura Vida Investments held 106 positions worth $338M, up 24% from $273M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Pura Vida Investments deployed $44.6M of net new capital in Q1 2017, opening 39 new positions and adding to 24 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 67,500 shares worth $8.18M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 53% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was AbbVie, an estimated $4.26M trimmed.

  • Pura Vida Investments's largest Q1 2017 buy was Alexion Pharmaceuticals: 67,500 shares worth $8.18M.
  • Pura Vida Investments added most to Allergan plc in Q1 2017, an estimated $5.16M increase.
  • Pura Vida Investments's biggest Q1 2017 reduction was AbbVie, cutting an estimated $4.26M.
  • Pura Vida Investments fully exited Athenahealth, Inc. in Q1 2017, selling an estimated $9.99M.
  • Pura Vida Investments's ten largest holdings make up 28% of its $338M portfolio in Q1 2017.
  • Pura Vida Investments opened 39 new positions and closed 28 in Q1 2017.
  • Pura Vida Investments's portfolio value rose 24% quarter-over-quarter to $338M.

Based on Pura Vida Investments's 13F filing for Q1 2017, filed 15 May 2017.